Early research (Phase 1)Ended earlyNCT03742349
What this trial is testing
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Who this might be right for
Triple Negative Breast Cancer (TNBC)
Novartis Pharmaceuticals 64